Skip to main content
. Author manuscript; available in PMC: 2013 Feb 1.
Published in final edited form as: J Immunol. 2011 Dec 21;188(3):1523–1533. doi: 10.4049/jimmunol.1102507

Figure 2. Destructive EBV positive lymphoproliferative disease.

Figure 2

A, Positron emission tomography (PET) scan of P5. Arrows indicate areas of high metabolic activity reflecting lymphoproliferative disease. B, Pulmonary CT scan of P5 showing a dense infiltrate of the left lower lobe. C-H, Lymph node histology: Giemsa staining of a tumor-free lymph node from a control patient with cancer (C) and the lymph node from P5 (D). Immunohistological staining of follicular dendritic cells (anti-CD21; E), B cells (anti-CD20; F) and T cells (anti-CD3; G). The anti-EBER (H) staining shows the presence of EBV infected cells. J-O, Lung histology: Immunohistological staining of cytokeratin (J), B cells (anti-CD20; K) and T cells (anti-CD3; M), that were predominantly CTL (anti-CD8; N) expressing high amounts of Granzyme B (O). The lung lesions were also highly positive for EBV infected cells (anti-EBER; L). The magnification was 2,5x (C-F,H and L), 5x (G,J and M) and 20x (K,N and O).